Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Projects / Programmes source: ARIS

Development of Mur Ligase Inhibitors as Novel Antibacterial Agents     

Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
P390  Natural sciences and mathematics  Organic chemistry 
P310  Natural sciences and mathematics  Proteins, enzymology 
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
Keywords
novel antibacterial agents, inhibitors, Mur ligases
Evaluation (rules)
source: COBISS
Evaluation of bibliographic research performance indicators according to ARIS methodology
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Researchers (2)
no. Code Name and surname Research area Role Period No. of publications
1.  20372  PhD Petra Štefanič  Pharmacy  Researcher  2005 - 2007  33 
2.  01878  PhD Uroš Urleb  Pharmacy  Head  2005 - 2007  380 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  8,436 
Abstract
The main purpose of the research project is the development of novel antibacterial agents. In order to challenge the infections caused by resistant bacterial strains novel targets are considered, among which the enzymes of bacterial cell wall synthesis Mur ligases are considered as most promising ones. Already published basic mechanistic features and crystal structures of Mur ligase enzymes as well as few known Mur inhibitors will give the starting point for development of novel potent Mur ligase inhibitors. Various modern techniques of rational drug design and organic synthesis will be applied in order to develop drug-like Mur ligase inhibitor candidate for clinical trials.
Confirmation required
Views history
Favourite